Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2016 (2016), Article ID 8605134, 6 pages
http://dx.doi.org/10.1155/2016/8605134
Review Article

Immune Regulation and Antitumor Effect of TIM-1

1Department of Tumor Biological Treatment, The Third Affiliated Hospital, Soochow University, Changzhou, Jiangsu 213003, China
2Jiangsu Engineering Research Center for Tumor Immunotherapy, Changzhou, Jiangsu 213003, China
3The Second People’s Hospital of Gansu Province, Lanzhou, Gansu 730000, China
4Department of Oncology, The 181st Hospital of PLA, Guilin, Guangxi 541002, China

Received 18 February 2016; Revised 10 April 2016; Accepted 28 April 2016

Academic Editor: Bin Zhang

Copyright © 2016 Peng Du et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. I. Silvestri, S. Cattarino, A. M. Aglianò, G. Collalti, and A. Sciarra, “Beyond the immune suppression: the immunotherapy in prostate cancer,” BioMed Research International, vol. 2015, Article ID 794968, 9 pages, 2015. View at Publisher · View at Google Scholar · View at Scopus
  2. K. H. Parker, D. W. Beury, and S. Ostrand-Rosenberg, “Myeloid-derived suppressor cells: critical cells driving immune suppression in the tumor microenvironment,” Advances in Cancer Research, vol. 128, pp. 95–139, 2015. View at Publisher · View at Google Scholar · View at Scopus
  3. D. J. Silver, M. Sinyuk, M. A. Vogelbaum, M. S. Ahluwalia, and J. D. Lathia, “The intersection of cancer, cancer stem cells, and the immune system: therapeutic opportunities,” Neuro-Oncology, vol. 18, no. 2, pp. 153–159, 2016. View at Publisher · View at Google Scholar
  4. L. Chen, J. V. Heymach, F. X.-F. Qin, and D. L. Gibbons, “The mutually regulatory loop of epithelial-mesenchymal transition and immunosuppression in cancer progression,” OncoImmunology, vol. 4, no. 5, Article ID e1002731, 2015. View at Publisher · View at Google Scholar · View at Scopus
  5. H.-W. Sun, C. Wu, H.-Y. Tan, and Q.-S. Wang, “A new development of FG-CC′ siRNA blocking interaction of Tim-1 and Tim-4 can enhance DC vaccine against gastric cancer,” Hepato-Gastroenterology, vol. 59, no. 120, pp. 2677–2682, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. S. Xiao, B. Zhu, H. Jin et al., “Tim-1 stimulation of dendritic cells regulates the balance between effector and regulatory T cells,” European Journal of Immunology, vol. 41, no. 6, pp. 1539–1549, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. W. Soo Hoo, E. R. Jensen, A. Saadat et al., “Vaccination with cell immunoglobulin mucin-1 antibodies and inactivated influenza enhances vaccine-specific lymphocyte proliferation, interferon-gamma production and cross-strain reactivity,” Clinical & Experimental Immunology, vol. 145, no. 1, pp. 123–129, 2006. View at Publisher · View at Google Scholar
  8. R. Rodriguez-Manzanet, R. Dekruyff, V. K. Kuchroo, and D. T. Umetsu, “The costimulatory role of TIM molecules,” Immunological Reviews, vol. 229, no. 1, pp. 259–270, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. C. Mariat, N. Degauque, S. Balasubramanian et al., “Tim-1 signaling substitutes for conventional signal 1 and requires costimulation to induce T cell proliferation,” The Journal of Immunology, vol. 182, no. 3, pp. 1379–1385, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. V. K. Kuchroo, D. T. Umetsu, R. H. DeKruyff, and G. J. Freeman, “The TIM gene family: emerging roles in immunity and disease,” Nature Reviews Immunology, vol. 3, no. 6, pp. 454–462, 2003. View at Publisher · View at Google Scholar · View at Scopus
  11. Y. Uchida, B. Ke, S. Cecilia et al., “The emerging role of t cell immunoglobulin mucin-1 in the mechanism of liver ischemia and reperfusion injury in the mouse,” Hepatology, vol. 51, no. 4, pp. 1363–1372, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. R. H. DeKruyff, X. Bu, A. Ballesteros et al., “T cell/transmembrane, Ig, and mucin-3 allelic variants differentially recognize phosphatidylserine and mediate phagocytosis of apoptotic cells,” The Journal of Immunology, vol. 184, no. 4, pp. 1918–1930, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. S. Xiao, C. R. Brooks, R. A. Sobel, and V. K. Kuchroo, “Tim-1 is essential for induction and maintenance of IL-10 in regulatory B cells and their regulation of tissue inflammation,” The Journal of Immunology, vol. 194, no. 4, pp. 1602–1608, 2015. View at Publisher · View at Google Scholar · View at Scopus
  14. M. L. Curtiss, B. S. Hostager, E. Stepniak et al., “Fyn binds to and phosphorylates T cell immunoglobulin and mucin domain-1 (Tim-1),” Molecular Immunology, vol. 48, no. 12-13, pp. 1424–1431, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. A. J. de Souza, J. S. Oak, R. Jordanhazy, R. H. DeKruyff, D. A. Fruman, and L. P. Kane, “T cell Ig and mucin domain-1-mediated T cell activation requires recruitment and activation of phosphoinositide 3-kinase,” The Journal of Immunology, vol. 180, no. 10, pp. 6518–6526, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. J. V. Bonventre, “Kidney injury molecule-1 (KIM-1): a specific and sensitive biomarker of kidney injury,” Scandinavian Journal of Clinical and Laboratory Investigation, vol. 68, no. 241, pp. 78–83, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. J. V. Bonventre, “Kidney injury molecule-1: a translational journey,” Transactions of the American Clinical and Climatological Association, vol. 125, pp. 293–299, 2014. View at Google Scholar
  18. A. K. Ajay, T.-M. Kim, V. Ramirez-Gonzalez, P. J. Park, D. A. Frank, and V. S. Vaidya, “A bioinformatics approach identifies signal transducer and activator of transcription-3 and checkpoint kinase 1 as upstream regulators of kidney injury molecule-1 after kidney injury,” Journal of the American Society of Nephrology, vol. 25, no. 1, pp. 105–118, 2014. View at Publisher · View at Google Scholar · View at Scopus
  19. T. Ichimura, C. R. Brooks, and J. V. Bonventre, “Kim-1/Tim-1 and immune cells: shifting sands,” Kidney International, vol. 81, no. 9, pp. 809–811, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. J. J. McIntire, S. E. Umetsu, O. Akbari et al., “Identification of Tapr (an airway hyperreactivity regulatory locus) and the linked Tim gene family,” Nature Immunology, vol. 2, no. 12, pp. 1109–1116, 2001. View at Publisher · View at Google Scholar · View at Scopus
  21. S.-C. Chae, Y.-R. Park, J.-H. Song, S.-C. Shim, K.-S. Yoon, and H.-T. Chung, “The polymorphisms of Tim-1 promoter region are associated with rheumatoid arthritis in a Korean population,” Immunogenetics, vol. 56, no. 10, pp. 696–701, 2005. View at Publisher · View at Google Scholar · View at Scopus
  22. S.-C. Chae, J.-H. Song, S.-C. Shim, K.-S. Yoon, and H.-T. Chung, “The exon 4 variations of Tim-1 gene are associated with rheumatoid arthritis in a Korean population,” Biochemical and Biophysical Research Communications, vol. 315, no. 4, pp. 971–975, 2004. View at Publisher · View at Google Scholar · View at Scopus
  23. M. Khademi, Z. Illés, A. W. Gielen et al., “T cell Ig- and mucin-domain-containing molecule-3 (TIM-3) and TIM-1 molecules are differentially expressed on human Th1 and Th2 cells and in cerebrospinal fluid-derived mononuclear cells in multiple sclerosis,” The Journal of Immunology, vol. 172, no. 11, pp. 7169–7176, 2004. View at Publisher · View at Google Scholar · View at Scopus
  24. X.-M. Zhang, N.-N. Shan, Y. Hu, and X. Wang, “Expression of TIM-1 and TIM-3 in spleen mononuclear cells and their role in Th1 polarization in primary immune thrombocytopenia patients,” Zhonghua Xue Ye Xue Za Zhi, vol. 34, no. 7, pp. 614–617, 2013. View at Google Scholar · View at Scopus
  25. X. Z. Cai, W. Y. Huang, Y. Qiao et al., “Downregulation of TIM-3 mRNA expression in peripheral blood mononuclear cells from patients with systemic lupus erythematosus,” Brazilian Journal of Medical and Biological Research, vol. 48, no. 1, pp. 77–82, 2015. View at Publisher · View at Google Scholar · View at Scopus
  26. J. A. Shim, E.-S. Lee, B. Choi, and S. Sohn, “The role of T cell immunoglobulin mucin domains 1 and 4 in a herpes simplex virus-induced Behçet's disease mouse model,” Mediators of Inflammation, vol. 2013, Article ID 903948, 13 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  27. K. Zheng, G. Xu, X. Lu, J. Zhang, and P. Zhang, “Expression and polymorphisms of T cell immunoglobulin domain and mucin domain protein-1 in thymoma with or without myasthenia gravis,” Oncology Letters, vol. 8, no. 1, pp. 317–322, 2014. View at Publisher · View at Google Scholar · View at Scopus
  28. Z. Li, Z. Ju, and M. Frieri, “The T-cell immunoglobulin and mucin domain (Tim) gene family in asthma, allergy, and autoimmunity,” Allergy and Asthma Proceedings, vol. 34, no. 1, pp. e21–e26, 2013. View at Publisher · View at Google Scholar · View at Scopus
  29. S. Hu, Y. Xie, N. Zhou et al., “Expression of T-cell immunoglobulin- and mucin-domain-containing molecules-1 and -3 (Tim-1 and Tim-3) in Helicobacter pylori infection,” Helicobacter, vol. 16, no. 5, pp. 373–381, 2011. View at Publisher · View at Google Scholar · View at Scopus
  30. O. Schweigert, C. Dewitz, K. Möller-Hackbarth et al., “Soluble T cell immunoglobulin and mucin domain (TIM)-1 and -4 generated by A Disintegrin And Metalloprotease (ADAM)-10 and -17 bind to phosphatidylserine,” Biochimica et Biophysica Acta—Molecular Cell Research, vol. 1843, no. 2, pp. 275–287, 2014. View at Publisher · View at Google Scholar · View at Scopus
  31. S. E. Umetsu, W.-L. Lee, J. J. McIntire et al., “TIM-1 induces T cell activation and inhibits the development of peripheral tolerance,” Nature Immunology, vol. 6, no. 5, pp. 447–454, 2005. View at Publisher · View at Google Scholar · View at Scopus
  32. I. D. Sizing, V. Bailly, P. McCoon et al., “Epitope-dependent effect of anti-murine TIM-1 monoclonal antibodies on T cell activity and lung immune responses,” Journal of Immunology, vol. 178, no. 4, pp. 2249–2261, 2007. View at Publisher · View at Google Scholar · View at Scopus
  33. X. Liu, X. Cui, D. Yuan et al., “Altered expression of T cell Immunoglobulin-Mucin (Tim) molecules in peripheral blood mononuclear cells in aplastic anemia,” Cancer Cell International, vol. 14, article 144, 2014. View at Publisher · View at Google Scholar · View at Scopus
  34. J. Lin, L. Chen, and L. P. Kane, “Murine Tim-1 is excluded from the immunological synapse,” F1000Research, vol. 1, article 10, 2012. View at Google Scholar
  35. M. L. Curtiss, J. V. Gorman, T. R. Businga et al., “Tim-1 regulates Th2 responses in an airway hypersensitivity model,” European Journal of Immunology, vol. 42, no. 3, pp. 651–661, 2012. View at Publisher · View at Google Scholar · View at Scopus
  36. C. Santiago, A. Ballesteros, L. Martínez-Muñoz et al., “Structures of T cell immunoglobulin mucin protein 4 show a metal-ion-dependent ligand binding site where phosphatidylserine binds,” Immunity, vol. 27, no. 6, pp. 941–951, 2007. View at Publisher · View at Google Scholar · View at Scopus
  37. L. L. Binné, M. L. Scott, and P. D. Rennert, “Human TIM-1 associates with the TCR complex and up-regulates T cell activation signals,” The Journal of Immunology, vol. 178, no. 7, pp. 4342–4350, 2007. View at Publisher · View at Google Scholar · View at Scopus
  38. S. Angiari, T. Donnarumma, B. Rossi et al., “TIM-1 glycoprotein binds the adhesion receptor P-selectin and mediates T cell trafficking during inflammation and autoimmunity,” Immunity, vol. 40, no. 4, pp. 542–553, 2014. View at Publisher · View at Google Scholar · View at Scopus
  39. S. Xiao, N. Najafian, J. Reddy et al., “Differential engagement of Tim-1 during activation can positively or negatively costimulate T cell expansion and effector function,” The Journal of Experimental Medicine, vol. 204, no. 7, pp. 1691–1702, 2007. View at Publisher · View at Google Scholar · View at Scopus
  40. J. H. Meyers, S. Chakravarti, D. Schlesinger et al., “TIM-4 is the ligand for TIM-1, and the TIM-1-TIM-4 interaction regulates T cell proliferation,” Nature Immunology, vol. 6, no. 5, pp. 455–464, 2005. View at Publisher · View at Google Scholar · View at Scopus
  41. N. Kobayashi, P. Karisola, V. Peña-Cruz et al., “TIM-1 and TIM-4 glycoproteins bind phosphatidylserine and mediate uptake of apoptotic cells,” Immunity, vol. 27, no. 6, pp. 927–940, 2007. View at Publisher · View at Google Scholar · View at Scopus
  42. M. Miyanishi, K. Tada, M. Koike, Y. Uchiyama, T. Kitamura, and S. Nagata, “Identification of Tim4 as a phosphatidylserine receptor,” Nature, vol. 450, no. 7168, pp. 435–439, 2007. View at Publisher · View at Google Scholar · View at Scopus
  43. N. Nurtanio and P.-C. Yang, “Role of TIM-4 in innate or adaptive immune response,” North American Journal of Medical Sciences, vol. 3, no. 5, pp. 217–221, 2011. View at Publisher · View at Google Scholar · View at Scopus
  44. S. Moller-Tank, A. S. Kondratowicz, R. A. Davey et al., “Role of the phosphatidylserine receptor TIM-1 in enveloped-virus entry,” Journal of Virology, vol. 87, no. 15, pp. 8327–8341, 2013. View at Google Scholar
  45. H.-H. Lee, E. H. Meyer, S. Goya et al., “Apoptotic cells activate NKT cells through T cell Ig-like mucin-like-1 resulting in airway hyperreactivity,” Journal of Immunology, vol. 185, no. 9, pp. 5225–5235, 2010. View at Publisher · View at Google Scholar · View at Scopus
  46. S. Angiari and G. Constantin, “Regulation of T cell trafficking by the T cell immunoglobulin and mucin domain 1 glycoprotein,” Trends in Molecular Medicine, vol. 20, no. 12, pp. 675–684, 2014. View at Publisher · View at Google Scholar · View at Scopus
  47. A. J. de Souza, T. B. Oriss, K. J. O'Malley, A. Ray, and L. P. Kane, “T cell Ig and mucin 1 (TIM-1) is expressed on in vivo-activated T cells and provides a costimulatory signal for T cell activation,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 47, pp. 17113–17118, 2005. View at Publisher · View at Google Scholar · View at Scopus
  48. Q. Ding, M. Yeung, G. Camirand et al., “Regulatory B cells are identified by expression of TIM-1 and can be induced through TIM-1 ligation to promote tolerance in mice,” Journal of Clinical Investigation, vol. 121, no. 9, pp. 3645–3656, 2011. View at Publisher · View at Google Scholar · View at Scopus
  49. N. Degauque, C. Mariat, J. Kenny et al., “Immunostimulatory Tim-1-specific antibody deprograms Tregs and prevents transplant tolerance in mice,” Journal of Clinical Investigation, vol. 118, no. 2, pp. 735–741, 2008. View at Publisher · View at Google Scholar · View at Scopus
  50. S. Xiao, C. R. Brooks, C. Zhu et al., “Defect in regulatory B-cell function and development of systemic autoimmunity in T-cell Ig mucin 1 (Tim-1) mucin domain-mutant mice,” Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 30, pp. 12105–12110, 2012. View at Publisher · View at Google Scholar · View at Scopus
  51. S. Sattler, G.-S. Ling, D. Xu et al., “IL-10-producing regulatory B cells induced by IL-33 (BregIL-33) effectively attenuate mucosal inflammatory responses in the gut,” Journal of Autoimmunity, vol. 50, pp. 107–122, 2014. View at Publisher · View at Google Scholar · View at Scopus
  52. S. Rong, J.-K. Park, T. Kirsch et al., “The TIM-1:TIM-4 pathway enhances renal ischemia-reperfusion injury,” Journal of the American Society of Nephrology, vol. 22, no. 3, pp. 484–495, 2011. View at Publisher · View at Google Scholar · View at Scopus
  53. S. Balasubramanian, S. K. Kota, V. K. Kuchroo, B. D. Humphreys, and T. B. Strom, “TIM family proteins promote the lysosomal degradation of the nuclear receptor NUR77,” Science Signaling, vol. 5, no. 254, article ra90, 2012. View at Publisher · View at Google Scholar · View at Scopus
  54. K. M. Lee, J. I. Kim, R. Stott et al., “Anti-CD45RB/anti-TIM-1-induced tolerance requires regulatory B cells,” American Journal of Transplantation, vol. 12, no. 8, pp. 2072–2078, 2012. View at Publisher · View at Google Scholar · View at Scopus
  55. X. Shi, M. Zhang, F. Liu et al., “Tim-1-Fc suppresses chronic cardiac allograft rejection and vasculopathy by reducing IL-17 production,” International Journal of Clinical and Experimental Pathology, vol. 7, no. 2, pp. 509–520, 2014. View at Google Scholar · View at Scopus
  56. Y. Zhang, H. Ji, X. Shen et al., “Targeting TIM-1 on CD4 T cells depresses macrophage activation and overcomes ischemia-reperfusion injury in mouse orthotopic liver transplantation,” American Journal of Transplantation, vol. 13, no. 1, pp. 56–66, 2013. View at Publisher · View at Google Scholar · View at Scopus
  57. S. Nakae, M. Iikura, H. Suto et al., “TIM-1 and TIM-3 enhancement of Th2 cytokine production by mast cells,” Blood, vol. 110, no. 7, pp. 2565–2568, 2007. View at Publisher · View at Google Scholar · View at Scopus
  58. H. Y. Kim, Y.-J. Chang, Y.-T. Chuang et al., “T-cell immunoglobulin and mucin domain 1 deficiency eliminates airway hyperreactivity triggered by the recognition of airway cell death,” Journal of Allergy and Clinical Immunology, vol. 132, no. 2, pp. 414–425.e6, 2013. View at Publisher · View at Google Scholar · View at Scopus
  59. D. Coe, C. Addey, M. White, N. Harwood, J. Dyson, and J.-G. Chai, “Distinct in vivo CD8 and CD4 T cell responses against normal and malignant tissues,” Cancer Immunology, Immunotherapy, vol. 62, no. 1, pp. 101–112, 2013. View at Publisher · View at Google Scholar · View at Scopus
  60. J. Jiang, C. Wu, and B. Lu, “Cytokine-induced killer cells promote antitumor immunity,” Journal of Translational Medicine, vol. 11, no. 1, article 83, 2013. View at Publisher · View at Google Scholar
  61. J. Galon, A. Costes, F. Sanchez-Cabo et al., “Type, density, and location of immune cells within human colorectal tumors predict clinical outcome,” Science, vol. 313, no. 5795, pp. 1960–1964, 2006. View at Publisher · View at Google Scholar · View at Scopus
  62. W. Zou, “Immunosuppressive networks in the tumour environment and their therapeutic relevance,” Nature Reviews Cancer, vol. 5, no. 4, pp. 263–274, 2005. View at Publisher · View at Google Scholar · View at Scopus
  63. W. Zou, “Regulatory T cells, tumour immunity and immunotherapy,” Nature Reviews Immunology, vol. 6, no. 4, pp. 295–307, 2006. View at Publisher · View at Google Scholar · View at Scopus
  64. E. Bremer, “Targeting of the tumor necrosis factor receptor superfamily for cancer immunotherapy,” ISRN Oncology, vol. 2013, Article ID 371854, 25 pages, 2013. View at Publisher · View at Google Scholar
  65. X. Zang and J. P. Allison, “The B7 family and cancer therapy: costimulation and coinhibition,” Clinical Cancer Research, vol. 13, no. 18, part 1, pp. 5271–5279, 2007. View at Publisher · View at Google Scholar · View at Scopus
  66. Y. Nozaki, D. J. Nikolic-Paterson, H. Yagita, H. Akiba, S. R. Holdsworth, and A. R. Kitching, “Tim-1 promotes cisplatin nephrotoxicity,” American Journal of Physiology—Renal Physiology, vol. 301, no. 5, pp. F1098–F1104, 2011. View at Publisher · View at Google Scholar · View at Scopus
  67. Y. Cao, X. Zhou, X. Huang et al., “Correction: Tim-3 expression in cervical cancer promotes tumor metastasis,” PLoS ONE, vol. 11, no. 3, Article ID e0152830, 2016. View at Publisher · View at Google Scholar
  68. X. Gao, J. Yang, Y. He, and J. Zhang, “Quantitative assessment of TIM-3 polymorphisms and cancer risk in Chinese Han population,” Oncotarget, vol. 7, no. 24, pp. 35768–35775, 2016. View at Publisher · View at Google Scholar
  69. C. Cai, Y.-F. Xu, Z.-J. Wu et al., “Tim-3 expression represents dysfunctional tumor infiltrating T cells in renal cell carcinoma,” World Journal of Urology, vol. 34, no. 4, pp. 561–567, 2016. View at Publisher · View at Google Scholar · View at Scopus
  70. J. Patel, E. N. Bozeman, and P. Selvaraj, “Taming dendritic cells with TIM-3: another immunosuppressive strategy used by tumors,” Immunotherapy, vol. 4, no. 12, pp. 1795–1798, 2012. View at Publisher · View at Google Scholar · View at Scopus
  71. H. S. Kim, H. S. Kim, C. W. Lee, and D. H. Chung, “T cell Ig domain and mucin domain 1 engagement on invariant NKT cells in the presence of TCR stimulation enhances IL-4 production but inhibits IFN-γ production,” Journal of Immunology, vol. 184, no. 8, pp. 4095–4106, 2010. View at Publisher · View at Google Scholar · View at Scopus
  72. K. N. Pollizzi and J. D. Powell, “Integrating canonical and metabolic signalling programmes in the regulation of T cell responses,” Nature Reviews Immunology, vol. 14, no. 7, pp. 435–446, 2014. View at Publisher · View at Google Scholar · View at Scopus
  73. S. S. Chang, “Re: MPDL3280A (Anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer,” The Journal of Urology, vol. 194, no. 4, p. 956, 2015. View at Publisher · View at Google Scholar · View at Scopus
  74. H. Park, Y. Kim, J.-W. Sul et al., “Synergistic anticancer efficacy of MEK inhibition and dual PI3K/mTOR inhibition in castration-resistant prostate cancer,” Prostate, vol. 75, no. 15, pp. 1747–1759, 2015. View at Publisher · View at Google Scholar · View at Scopus
  75. F. Wang, Y. Mao, Q. You, D. Hua, and D. Cai, “Piperlongumine induces apoptosis and autophagy in human lung cancer cells through inhibition of PI3K/Akt/mTOR pathway,” International Journal of Immunopathology and Pharmacology, vol. 28, no. 3, pp. 362–373, 2015. View at Publisher · View at Google Scholar · View at Scopus
  76. Q. Zhang, H. Zhu, X. Xu, L. Li, H. Tan, and X. Cai, “Inactivated Sendai virus induces apoptosis and autophagy via the PI3K/Akt/mTOR/p70S6K pathway in human non-small cell lung cancer cells,” Biochemical and Biophysical Research Communications, vol. 465, no. 1, pp. 64–70, 2015. View at Publisher · View at Google Scholar · View at Scopus
  77. S. Raha, S. Yumnam, G. E. Hong et al., “Naringin induces autophagy-mediated growth inhibition by downregulating the PI3K/Akt/mTOR cascade via activation of MAPK pathways in AGS cancer cells,” International Journal of Oncology, vol. 47, no. 3, pp. 1061–1069, 2015. View at Publisher · View at Google Scholar · View at Scopus
  78. G. Li, Q. Yang, Y. Zhu et al., “T-bet and eomes regulate the balance between the effector/central memory T cells versus memory stem like T cells,” PLoS ONE, vol. 8, no. 6, Article ID e67401, 2013. View at Publisher · View at Google Scholar · View at Scopus
  79. J. R. Fergusson, M. H. Hühn, L. Swadling et al., “CD161intCD8+ T cells: a novel population of highly functional, memory CD8+ T cells enriched within the gut,” Mucosal Immunology, vol. 9, no. 2, pp. 401–413, 2015. View at Publisher · View at Google Scholar
  80. G. Xu, L. Cheng, W. Wen et al., “Inverse association between T-cell immunoglobulin and mucin domain-1 and T-bet in a mouse model of allergic rhinitis,” Laryngoscope, vol. 117, no. 6, pp. 960–964, 2007. View at Publisher · View at Google Scholar · View at Scopus
  81. L.-J. Chen, X. Zheng, Y.-P. Shen et al., “Higher numbers of T-bet+ intratumoral lymphoid cells correlate with better survival in gastric cancer,” Cancer Immunology, Immunotherapy, vol. 62, no. 3, pp. 553–561, 2013. View at Publisher · View at Google Scholar · View at Scopus
  82. E. W. Su, J. Y. Lin, and L. P. Kane, “TIM-1 and TIM-3 proteins in immune regulation,” Cytokine, vol. 44, no. 1, pp. 9–13, 2008. View at Publisher · View at Google Scholar · View at Scopus
  83. Z. Wang, J. Zhu, H. Gu et al., “The clinical significance of abnormal Tim-3 expression on NK cells from patients with gastric cancer,” Immunological Investigations, vol. 44, no. 6, pp. 578–589, 2015. View at Publisher · View at Google Scholar · View at Scopus